All In Biotech

Drug Trial Radar · NCT05106127

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab

Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Evergreen Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

Conditions

  • Advanced Endometrial Cancer

Interventions

  • EG-007Drug

    A Repurposed Drug

  • Pembrolizumab 100 mg/4 mL (25 mg/ml) InjectionDrug

    Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.

  • Lenvatinib CapsulesDrug

    Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events Assessment using CTCAE v5.0Time frame: 1 Cycle of 21 days
  2. Tolerability Score measurement using NCI-PRO CTCAETime frame: 1 Cycle of 21 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.